{"id":"susceptibility-test-guided-sequential-therapy","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a therapeutic approach rather than a single drug entity. It involves performing susceptibility tests on isolated pathogens to determine which antibiotics are most effective, then sequentially administering antibiotics based on test results to maximize clinical efficacy and minimize resistance development. The strategy is particularly used in treating infections where empiric broad-spectrum therapy is initially given, then narrowed or adjusted based on culture and susceptibility data.","oneSentence":"A clinical strategy that uses antimicrobial susceptibility testing to guide sequential antibiotic therapy selection for optimal pathogen coverage.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:10:18.875Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections requiring sequential antibiotic therapy guided by susceptibility testing"}]},"trialDetails":[{"nctId":"NCT04332848","phase":"PHASE4","title":"Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2020-07-28","conditions":"Helicobacter Pylori Infection","enrollment":360},{"nctId":"NCT07130253","phase":"NA","title":"Efficacy of Vonoprazan-based Rescue Therapy for H. Pylori Eradication","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-08-18","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":220},{"nctId":"NCT05549115","phase":"NA","title":"Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Liaocheng People's Hospital","startDate":"2022-09-20","conditions":"Helicobacter Pylori Infection","enrollment":500},{"nctId":"NCT02373280","phase":"NA","title":"The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-08","conditions":"Helicobacter Infection","enrollment":600},{"nctId":"NCT03556254","phase":"PHASE4","title":"Genotypic Resistance Guided Versus Susceptibility Testing Guided Therapy for the First-line Eradication of H. Pylori","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2018-03-29","conditions":"Helicobacter Pylori Infection","enrollment":560},{"nctId":"NCT03555526","phase":"PHASE4","title":"Genotypic Resistance Guided Therapy for Refractory H. Pylori Infection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2017-12-15","conditions":"H Pylori Infection","enrollment":320},{"nctId":"NCT01032655","phase":"PHASE4","title":"The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2009-04","conditions":"Helicobacter Pylori Infection","enrollment":134}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"susceptibility test guided sequential therapy","genericName":"susceptibility test guided sequential therapy","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A clinical strategy that uses antimicrobial susceptibility testing to guide sequential antibiotic therapy selection for optimal pathogen coverage. Used for Bacterial infections requiring sequential antibiotic therapy guided by susceptibility testing.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}